The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies

Canadian Journal of Cardiology

Volumn 31, Issue 12, 2015, Pages 1421-1426

  Desplantie, Olivier ^a   Tremblay Gravel, Maxime ^a   Avram, Robert ^a   Marquis Gravel, Guillaume ^a   Ducharme, Anique ^b   Jolicoeur, E Marc ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; LEVOSIMENDAN; PENTOXIFYLLINE; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

CONCEPTION; ECHOCARDIOGRAPHY; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MORTALITY; PERIPARTUM CARDIOMYOPATHY; PLEIOTROPY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; CARDIOMYOPATHIES; DRUG EFFECTS; FEMALE; HEART LEFT VENTRICLE FUNCTION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROSPECTIVE STUDY; PUERPERAL DISORDERS; SURVIVAL RATE;

BROMOCRIPTINE; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYDRAZONES; PENTOXIFYLLINE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROSPECTIVE STUDIES; PUERPERAL DISORDERS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84936127380     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.04.029     Document Type: Review

References (49)

1. Harper M.A., Meyer R.E., Berg C.J. Peripartum cardiomyopathy: population-based birth prevalence and 7-year mortality. Obstet Gynecol 2012, 120:1013-1019.
2. Duran N., Gunes H., Duran I., Biteker M., Ozkan M. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet 2008, 101:137-140.
3. Haghikia A., Podewski E., Libhaber E., et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013, 108:366.
4. Howlett J.G., McKelvie R.S., Costigan J., et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 2010, 26:185-202.
5. Hilfiker-Kleiner D., Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 2014, 11:364-370.
6. Demakis J.G., Rahimtoola S.H., Sutton G.C., et al. Natural course of peripartum cardiomyopathy. Circulation 1971, 44:1053-1061.
7. Sliwa K., Forster O., Libhaber E., et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006, 27:441-446.
8. Sliwa K., Hilfiker-Kleiner D., Petrie M.C., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010, 12:767-778.
9. Gunderson E.P., Croen L.A., Chiang V., et al. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 2011, 118:583-591.
10. Pearson G.D., Veille J.C., Rahimtoola S., et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000, 283:1183-1188.
11. Lampert M.B., Hibbard J., Weinert L., et al. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol 1993, 168:493-495.
12. Horne B., Rasmusson K., Rami Alharethi R., et al. Peripartum cardiomyopathy-associated sequence variant at the PTHLH locus is not predictive of idiopathic or ischemic cardiomyopathy (abstract). Circulation 2011, 124:A16347.
13. Diao M., Diop I.B., Kane A., et al. Electrocardiographic recording of long duration (Holter) of 24 hours during idiopathic cardiomyopathy of the peripartum. Arch Mal Coeur Vaiss 2004, 97:25-30. in French.
14. Desai D., Moodley J., Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995, 25:118-123.
15. Barasa A., Rosengren A., Ladfors L., Swedberg K., Schaufelberger M. Longterm mortality in 272 women with peripartum cardiomyopathy (abstract). Circulation 2012, 126:A18643.
16. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 2011, 58:659-670.
17. Goland S., Modi K., Bitar F., et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009, 15:645-650.
18. Sliwa K., Blauwet L., Tibazarwa K., et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010, 121:1465-1473.
19. Biteker M., Duran N.E., Kaya H., et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol 2011, 100:571-577.
20. Sliwa K., Skudicky D., Candy G., et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 2002, 4:305-309.
21. Negoro S., Kunisada K., Fujio Y., et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001, 104:979-981.
22. Patten I.S., Rana S., Shahul S., et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012, 485:333-338.
23. Lkhider M., Castino R., Bouguyon E., Isidoro C., Ollivier-Bousquet M. Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. J Cell Sci 2004, 117:5155-5164.
24. Ferrara N., Clapp C., Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991, 129:896-900.
25. Singh N., Dhalla A.K., Seneviratne C., Singal P.K. Oxidative stress and heart failure. Mol Cell Biochem 1995, 147:77-81.
26. Hilfiker-Kleiner D., Kaminski K., Podewski E., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007, 128:589-600.
27. Iffy L., Lindenthal J., Mcardle J., Ganesh V. Severe cerebral accidents postpartum in patients taking bromocriptine for milk suppression. Isr J Med Sci 1996, 32:309-312.
28. Cheryl L., Dragovic L. Acute coronary artery thrombosis in a postpartum woman receiving bromocriptine. Am J Forensic Med Pathol 1998, 19:258-260.
29. Hopp L., Weisse A., Iffy L. Acute myocardial infarction in a healthy mother using bromocriptine for milk suppression. Can J Cardiol 1996, 12:415-418.
30. Larrazet F., Spaulding C., Lobreau H., Weber S., Guerin F. Possible bromocriptine-induced myocardial infarction. Ann Intern Med 1993, 118:199-200.
31. Eickman F. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin Cardiol 1992, 15:781-783.
32. de Jong-van den Berg L., Mintzes B. Bromocriptine and lactation suppression: are the risks acceptable?. Pharm World Sci 1995, 17:93-95.
33. Krupp P., Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987, 65:823-827.
34. Serratrice J., Disdier P., Habib G., Viallet F., Weiller P.J. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002, 10:334-336.
35. Schade R., Andersohn F., Suissa S., Haverkamp W., Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007, 356:29-38.
36. Hilfiker-Kleiner D., Meyer G., Schieffer E., et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007, 50:2354-2355.
37. Jahns B., Stein W., Hilfiker-Kleiner D., Pieske B., Emons G. Peripartum cardiomyopathy-a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol 2008, 199:e5-6.
38. Dutt S., Wong F., Spurway J.H. Fatal myocardial infarction associated with bromocriptine for postpartum lactation suppression. Aust N Z J Obstet Gynaecol 1998, 38:116-117.
39. Papp Z., Csapo K., Pollesello P., Haikala H., Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005, 23:71-98.
40. Haikala H., Kaheinen P., Levijoki J., Lindén I. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997, 34:536-546.
41. Sorsa T., Pollesello P., Rosevear P., Drakenberg T., Kilpeläinen I. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol 2004, 486:1-8.
42. De Luca L., Colucci W.S., Nieminen M.S., Massie B.M., Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006, 27:1908-1920.
43. McMurray J., Adamopoulos S., Anker S., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
44. Finkel M., Oddis C., Jacob T., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
45. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
46. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
47. Skudicky D., Bergemann A., Sliwa K., Candy G., Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001, 103:1083-1088.
48. Sliwa K., Skudicky D., Candy G., Wisenbaugh T., Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998, 351:1091-1093.
49. Stevens J., Simpson E., Harnan S., et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012, 99:1630-1638.